NCT06555432View on ClinicalTrials.gov

A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

RecruitingOBSERVATIONAL
Enrollment

168

Participants

Timeline

Start Date

November 14, 2024

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2028

Conditions
Cytomegalovirus (CMV)
Interventions
DRUG

LIVTENCITY

LIVTENCITY tablet.

Trial Locations (1)

06591

RECRUITING

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY